Joel W. Neal, MD, PhD, of Stanford Cancer Institute, discusses updated overall survival data from cohort C of the CHRYSALIS-2 trial, which looked at first-line amivantamab plus lazertinib in previously untreated patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC) (Abstract 8501).
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).
Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508).
Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international randomized controlled trial comparing chemotherapy decisions made with the Prosigna (PAM50) gene expression test with standard treatment in mostly node-positive patients with high clinical risk ER-positive HER2-negative early breast cancer (Abstract 500).
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).
Richard Cathomas, MD, of Cantonal Hospital Graubünden, reviews results from the primary analysis of SAKK 06/19, an open-label single arm phase II trial, which found that the combination of intravesical recombinant bacillus Calmette-Guérin (BCG) with atezolizumab, cisplatin, and gemcitabine was feasible and safe without unexpected toxicities and demonstrates promising efficacy in patients with muscle-invasive bladder cancer (MIBC) (Abstract 4503).
